Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

non-alcoholic steatohepatitis drugs

- PMLiVE

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Sets stage for lower-cost competition to big-selling drug

- PMLiVE

FDA rejects ViiV’s long-acting monthly HIV injection

Blow to company as it hopes to capture market share from Gilead

- PMLiVE

Gilead’s NASH hopes crushed as candidates fail again

Monotherapy and combination regimens produced disappointing results

- PMLiVE

Gilead owes BMS millions after losing Yescarta patent infringement trial

Jury found Gilead's CAR-T infringed on exclusive patent

Bristol Myers Squibb logo

BMS’ oral maintenance therapy boosts survival in AML patients

Drug improved survival by almost ten months

- PMLiVE

J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data

Both candidates are being studied in multiple myeloma

Bristol Myers Squibb logo

Armed with new data, BMS plans filings for Celgene CAR-T liso-cel

Achieved a 53% complete response rate in study participants

Bristol Myers Squibb logo

BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

Could win approval in group of rare blood cancers

- PMLiVE

CymaBay Therapeutics plummets after abandoning NASH drug

Failure of mid-stage liver disease candidate caused shares to slip over 75%

- PMLiVE

Amgen raises forecasts after closing $13.4bn Otezla deal

Scope to build product further with ongoing trials in additional indications

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combination fails to shine in melanoma

Combo therapy did not show significant benefit in key patient population

Celgene building

UPDATED: BMS completes Celgene merger after FTC okay

Approval comes over ten months after acquisition announcement

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links